Professor Constantine Stratakis  co-chaired a meet the expert session at the 31st European Meeting on Hypertension and Cardiovascular Protection.  He summarized us the main messages of the session on the diagnosis and management of primary aldosteronism. 

Video: https://congressreport.eu/scientific-contents/interview:novelties-diagnosis-and-management-primary-aldosteronism

Professor Takayuki Yoshino presented at the recent ASCO 2022 new data about the PARADIGM trial. He summerized us the main findings. (Panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first‐line treatment in patients with RAS wild‐type metastatic colorectal cancer)

Video: https://congressreport.eu/scientific-contents/interview:results-phase-3-paradigm-trial

Professor Florian Kronenberg presented the lipoprotein(a) consensus panel recommendations in the recent European Atherosclerosis Society 2022 Congress in Milan. He summarized for us our current knowledge about the role of lipoprotein(a) in cardiovascular diseases.

Video: https://congressreport.eu/scientific-contents/interview:detecting-elevated-lipoprotein-and-addressing-ascvd-risks

Professor Carl Orringer was a co-chair of a recent symposium at the European Atherosclerosis Society 2022 session in Milan. The topic of the discussion was the potential role of the injectable therapies to prevent cardiovascular disease.

Video: https://congressreport.eu/scientific-contents/interview:who-needs-injectable-therapies-cholesterol-lowering-or-statins-and-ezetimibe-are-enough-cvd-prevention

Professor Richard D. Kim presented a data about the long term follow-up of the KEYNOTE-651 study at the recent ASCO 2022 congress. We asked him about the new informations and also about the KEYNOTE-177 trial.

Video: https://congressreport.eu/scientific-contents/interview:pembrolizumab-crc-what-did-we-learn-keynote-177-and-keynote-651-trials

Professor Giuseppe Danilo Norata discussed in the interview what is difference between PCSK9 genetic deficiency and PCSK9 pharmacological inhibition.

Video: https://congressreport.eu/scientific-contents/interview:difference-between-genetic-and-pharmacological-inhibition-pcsk9

Professor Sibylle Loibl was the recipient of the 2022 ESMO Breast Cancer award for her excepcional contribution the clinical research of Breast Cancer. We asked her about the award an the upcoming new clinical practice guidelines of ESMO for the diagnosis, treatment and follow-up for early breast cancer, which will be published at the ESMO 2022 congress in September.

Video: https://congressreport.eu/scientific-contents/interview:early-breast-cancer-esmo-clinical-practice-guidelines-diagnosis-treatment-and-follow-

Dr. Andrew Blauvelt is the first author of a recent paper which analyzes long-term efficacy and safety of ixekizumab in psoriasis. Dr. Blauvelt tell us what was the message of this study for the dermatologist society and why it is important for their patients.

Video: https://congressreport.eu/scientific-contents/standalonecontent:long-term-efficacy-and-safety-ixekizumab

The full article:

Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial

https://www.jaad.org/article/S0190-9622(20)33053-X/fulltext

Professor Ulrich Laufs talk about a very challenging topic, secondary cardiovascular prevention. At the European Atherosclerosis Society annual meeting he had a lecture, the ESC/EAS joint session about the societies prevention guideline, focusing on secondary prevention.

Video: https://congressreport.eu/scientific-contents/interview:esceas-joint-session-what-new-secondary-cv-prevention

Professor Ian Graham shared us the advances of the cardiovascular risk collaboration he spoke about of the ESC/EAS joint session at EAS 2022.

Video: https://congressreport.eu/scientific-contents/interview:esceas-joint-session-advances-cv-risk-estimation-focus-dyslipidemia